Massachusetts Financial Services Co. MA Sells 14,608 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Massachusetts Financial Services Co. MA lessened its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 13.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,171 shares of the company’s stock after selling 14,608 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.20% of Nurix Therapeutics worth $2,049,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of NRIX. GAMMA Investing LLC lifted its holdings in Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after purchasing an additional 3,424 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Nurix Therapeutics during the fourth quarter valued at about $59,000. EntryPoint Capital LLC bought a new stake in Nurix Therapeutics during the 1st quarter worth approximately $123,000. China Universal Asset Management Co. Ltd. lifted its stake in Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after purchasing an additional 3,793 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares during the period.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,408 shares of the business’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $70,443.36. Following the transaction, the insider now owns 45,150 shares in the company, valued at approximately $933,250.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $51,468.30. Following the sale, the chief financial officer now owns 54,479 shares of the company’s stock, valued at approximately $1,126,080.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,408 shares of the business’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $70,443.36. Following the transaction, the insider now owns 45,150 shares in the company, valued at approximately $933,250.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 59,815 shares of company stock worth $1,416,751. 7.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Barclays upped their price target on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Truist Financial began coverage on Nurix Therapeutics in a report on Wednesday, July 31st. They issued a “buy” rating and a $36.00 price target on the stock. Oppenheimer boosted their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Robert W. Baird started coverage on shares of Nurix Therapeutics in a research report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price objective on the stock. Finally, Needham & Company LLC dropped their target price on shares of Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, July 12th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Nurix Therapeutics Stock Up 2.2 %

NASDAQ NRIX opened at $25.62 on Monday. The company has a 50-day simple moving average of $22.96 and a two-hundred day simple moving average of $18.34. Nurix Therapeutics, Inc. has a 12-month low of $4.22 and a 12-month high of $26.31. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -8.77 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The company had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $19.35 million. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.